Relugolix Combination Therapy
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Contraception
Conditions
Contraception
Trial Timeline
Mar 18, 2021 → Feb 1, 2026
NCT ID
NCT04756037About Relugolix Combination Therapy
Relugolix Combination Therapy is a phase 3 stage product being developed by Sumitomo Pharma for Contraception. The current trial status is active. This product is registered under clinical trial identifier NCT04756037. Target conditions include Contraception.
What happened to similar drugs?
15 of 20 similar drugs in Contraception were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04756037 | Phase 3 | Active |
Competing Products
20 competing products in Contraception